Clinical trial NCT02156154
Conditions: Postoperative Pain
Sponsor: The Cleveland Clinic
Start date: 2014-12-01; Completion date: 2020-10-01
Enrollment: 580 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Some patients have respiratory depression (decreased breaths per minute) after surgery. Acetaminophen, an FDA approved pain medication, may prevent this problem. The purpose of this study is to determine if acetaminophen decreases respiratory depression after surgery. The investigators will also evaluate the cost effectiveness of acetaminophen.

Patients having elective major abdominal surgery are being asked to participate in this research study. If eligible, a patient will have their baseline tidal volume (amount of air moved into or out of the lungs) and vital capacity (how much air the lungs are capable of holding) measured using a spirometer (apparatus for measuring the volume of air inspired and expired by the lungs) measured before surgery. Three questionnaires will also need to be completed before surgery.

The patient will then be randomized, like flipping a coin, to receive either Acetaminophen or placebo (inactive substance) as an infusion throughout surgery and for the first two days thereafter. Neither the patient nor his or her physician will know if the patient is assigned to study drug or placebo. Regardless of study assignment, both groups will receive standard pain management medications and sedation.

After surgery, the patient's blood pressure, activity, posture, respiratory rate, the electrical activity of the heart, oxygen saturation, tidal volume, minute ventilation and respiratory rate will be continuously monitored and recorded for 48 hours using a wireless pulse-oximeter and a respiratory volume monitor.

48 hours after surgery the patient will be asked to complete a patient satisfaction questionnaire, which will allow the patient to rate the satisfaction with the treatment received for pain. The patient will also be asked to complete a questionnaire about recovery.

At discharge, the patient will be given two questionnaires about pain and quality of life.

Detailed description:

Arms: arm 1: 0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge. arm 2: Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
Interventions: intervention 1: Intravenous Acetaminophen
Intervention descriptions: intervention 1: None

Protocol documents:
Prot_SAP_000.pdf: 
 
 
 
 
 
 
 
 
Effect of Intravenous Acetaminophen on 
Postoperative Opioid-related Complications 
– FACTOR – 
 
Alparslan Turan, M.D. and Colleagues  
 
Department of OUTCOMES RESEARCH 
Cleveland Clinic 
January 09, 2015 
NCT02156154 
 
 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
2 
 
 
Table of Contents 
 
 
1 INTRODUCTION 
1.1 Background 
A. Postoperative pain 
B. Postoperative pain management and Multimodal Analgesia  
C. Opioid Analgesics and side effects 
D. Acetaminophen 
E. Rationale of the study 
2 STUDY OBJECTIVES 
3 METHODS and STUDY DESIGN 
A. Study Overview 
B. Setting and Population 
Inclusion Criteria 
Exclusion Criteria 
C. Withdrawal Criteria  
D. Administration of Acetaminophen  
E. Protocol 
F. Measurements 
G. Data Analysis 
H. Sample Size Considerations 
I. References 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
3 
 
 
1. INTRODUCTION 
1.1 Background 
A. Postoperative pain 
Pain is a psychological sensory experience which is caused by various factors. 
Surgery results in tissue damage which leads to postoperative pain. Studies in recently 
developed animal models of postoperative pain have advanced our knowledge of the 
mechanisms of pain resulting from surgical incision and associated tissue injury. 
Postoperative pain results from a of combination of nociceptive and inflammatory 
components.(1) The nociceptive component results from activation of peripheral sensory 
neurons damaged by surgical incision, and fades gradually as tissues heal. The 
inflammatory component enhances pain sensitivity via release of mediators from the 
surgically injured tissue. Central neuronal sensitization also seems to contribute to 
postoperative pain and hyperalgesia. (1, 2) Due to aforementioned mechanisms pain is 
present in spontaneous resting at the site of surgery plus surrounding tissues. Movement 
or touching of the wound site, breathing, coughing, and gastrointestinal motility can all 
evoke pain.  
Unrelieved postoperative postoperative pain leads to multiple physiological and 
psychological consequences which worsen outcomes. For example, inadequate 
perioperative analgesia is associated with myocardial ischemia, impaired wound healing, 
delayed gastrointestinal motility, atelectasis, and postoperative pneumonia. (3, 4,5) 
Furthermore, poorly controlled acute pain is strongly associated with development of 
persistent incisional pain which can be devastating for patients. (6, 7) 
 
B. 
Multimodal 
Postoperative 
Analgesia 
With 
Non-steroidal 
Anti-
inflammatory Drugs 
Postoperative pain management has improved, but remains a major problem. 
Patients still report that 31% of them suffer from severe pain and 47% from moderate pain 
after surgery.(8) Researchers have estimated that only one in four surgical patients in the 
USA received adequate relief of acute pain. Consequently, postoperative pain remains 
the major preoperative concern for patients having surgery. (9)  
Pain involves multiple mechanisms and is thus ideally treated with a variety of 
analgesic techniques with additive or synergistic effects. (1) In theory, at least, combining 
techniques improves overall analgesia while reducing side effects. Consistent with this 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
4 
theory, studies indicate that multimodal analgesia shortens hospitalization times, 
improves recovery and function, and decreases health care costs. (1, 10) 
Multimodal analgesia can be achieved by combining many different classes of 
drugs. (1,10,11) But the most common approaches are a combination of an opioid and 
non-opioid with or without regional anesthesia-analgesia.(11) The main goal is to 
decrease opioid use and consequently decrease the incidence of opioid related side 
effects. Non-opioid analgesics used in this setting are generally insufficient to treat 
postoperative pain by themselves, but have substantial opioid-sparing effects and thus 
presumably reduce opioid-related complications. While logical, there is in fact limited 
evidence that reducing opioid consumption actually decreases opioid-related 
complications — especially life-threatening complications such as respiratory depression. 
The most common drug groups used for multimodal analgesia are non-steroidal 
anti-inflammatory drugs (NSAIDs) and acetaminophen, and the distinction is important. 
NSAIDs are antipyretic and anti-inflammatory, but provoke surgical and gastrointestinal 
bleeding, renal impairment; they also impair bone healing. (11, 12,13) In contrast, 
acetaminophen is a “pure” analgesic with few side effects, and none likely to harm surgical 
patients. It is beyond question that acetaminophen is opioid-sparing; however, there are 
no large randomized trials evaluating whether opioid sparing actually reduces 
complications as expected.(13) 
C. Opioid Analgesics and side effects 
Opioids are the most common treatment for postoperative pain. Opioids produce 
analgesia and other effects by binding to specific opioid receptors in the peripheral and 
central nervous system. Three types of opioid receptors and their subtypes have been 
discovered: mu, delta, and kappa receptors. The most commonly used opioids bind to mu 
receptors. The mu1 receptor is responsible for the production of opioid-induced analgesia, 
whereas the mu2 receptors are related to the respiratory depression, cardiovascular 
effects, and inhibition of gastrointestinal motility commonly seen with opioids.(14,15,16)  
There is a persistent misconception that pain, no matter how severe, can always 
be effectively relieved by opioids. That is certainly not the case at doses which can be 
safely used postoperatively, and numerous studies show that postoperative analgesia 
remains inadequate in a striking fraction of patients. (8) Acute tolerance and opioid-
induced hyperalgesia increase opioid requirements, in turn increasing the risk of side 
effects.  
The most serious opioid-induced complication is respiratory depression which 
results from a dose-dependent reduction in responsiveness of brainstem respiratory 
centers to carbon dioxide (Pco2) with opioids. This is clinically manifested as an increase 
in resting Pco2 and a shift in the CO2 response curve. (17,18) Respiratory depression is 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
5 
the main fatal hazard of opioid use and has been identified as a safety target by the Joint 
Commission on Hospital Accreditation (19). Supporting this concern, a study conducted 
in United Kingdom ranked opioids as the second most common cause of adverse events 
in hospitalized patients.(20) The current national goal of better controlling postoperative 
pain by making it a quality indicator is likley to increase opioid use — and almost surely 
also increase associated complications.  
Sedation is another serious consequence of excessive opioid use, and often 
impairs patient mobility and postoperative recovery. For example, sedation decreases 
ambulation and thus promotes atelectasis and respiratory depression.(21) There are 
currently no widely accepted guidelines or monitoring practices for opioid-related sedation 
and the respiratory depression. The Anesthesia Patient Safety Foundation suggests 
using continuous monitoring of pulse oximetry in patients receiving patient-controlled 
analgesia (PCA).(22) However, continuous pulse oximetry is in fact rarely used.  
Postoperative nausea and vomiting (PONV) is the most common opioid-related 
complication and is caused by stimulation of the chemoreceptor trigger zone of the 
medulla.(23) Furthermore, opioids enhance sphincter tone and reduce peristaltic 
contraction. Delayed gastric emptying is caused by decreased motility, increased antral 
tone, and increased tone in the first part of the duodenum. Delay in passage of intestinal 
contents leads to greater absorption of water, increased viscosity, and desiccation of 
bowel contents — which in turn causes constipation and contributes to postoperative 
ileus.(24) Postoperative ileus, with an incidence of 4.5%, prolongs hospital stay and 
increases hospital costs.(25) Opioids also inhibit urinary bladder function, thus increasing 
the risk of urinary retention.  
In summary, opioids provoke numerous severe complications that cause 
substantial patient morbidity. They also delay discharge from hospital, increase the cost 
of care, and reduce patient satisfaction. 
D. Acetaminophen 
Acetaminophen is a derivative of p-aminophenol. It is also known in many 
countries by the name paracetamol. Acetaminophen is a centrally acting analgesic and 
antipyretic agent which has been in use for decades. Acetaminophen centrally inhibits 
prostaglandins via the COX pathway, by selective inhibition of COX-2-dependent 
prostaglandin E2 formation (13,26). The drug reinforces descending serotonergic 
inhibitory pain pathways (26,27), indirectly activates cannabinoid CB1 receptors (13, 27, 
28), and inhibits nitric oxide pathways (8) through N-methyl-D-aspartate or substance P 
(29). Acetaminophen also appears to be a TRPV-1 agonist.  
Acetaminophen is generally considered to be analgesic, without anti-inflammatory 
properties. However, recent human studies identify anti-inflammatory effects similar to 
those of ibuprofen; animal studies similarly indicate that acetaminophen inhibits 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
6 
inflammation and edema.(13) Acetaminophen is thus now thought to provide weak anti-
inflammatory properties compared to other NSAIDs. 
The recommended dosage of acetaminophen is 1 g every 6 hours, or 650 mg 
every 4 hours, with maximum of 4 g/day. Acetaminophen IV reaches maximum 
concentration (C max) at the end of a 15-minute infusion. The C max ranges from 28 to 
31 µg/mL. The clearance ranges from 0.27 to 0.34 L/hour/kg, and the volume-of-
distribution ranges from 0.8 to 1.2 L/kg. Acetaminophen IV has low plasma protein binding 
and thus distributes widely through the body tissues except to fat.(13,30,31,32,33)  
Acetaminophen has a mean half-life of 2.4 ± 0.6 hours and is metabolized primarily 
in the liver, with 5% of free drug excreted in urine. Use of acetaminophen in perioperative 
settings is relatively new, but is becoming more common now that an intravenous 
formulation is available. There are numerous reasons to prefer acetaminophen to 
traditional NSAIDs. Among the most important is that recommended doses of 
acetaminophen do not interfere with platelet function, and thus do not promote bleeding. 
And unlike NSAIDs, acetaminophen has little effect on the kidney and gastrointestinal 
system.(13,30,31,32,33) 
Several metanalyses summarize available studies of perioperatrive intravenous 
acetaminophen use. Remy et al. (34) evaluated the morphine sparing effect of 
intravenous acetaminophen after major surgery in 7 clinical trials and demonstrated a 
significant 10-mg decrease in morphine consumption on first postoperative day. The 
decrease was not associated with reduction in opioid-related adverse event, although the 
total number of patients included in the analysis was limited. In another metanalysis, Elia 
et al. (35) evaluated opoid sparing with various NSAIDs and acetaminophen. they 
included 10 trials of acetaminophen analgesia after major surgery and identified a 
significant 8-mg reduction in morphine consumption, but again no significant decrease in 
opioid-related side effects. Finally, a recent metanalysis by Apfel, Turan, and colleagues 
(36) included 30 studies, and demonstrated a significant reduction in pain and opioid use 
with intravenous acetaminophen, along with a significant reduction in PONV. The most 
likely reason previous acetaminophen studies failed to identify significant reductions in 
opioid-related complications is that all were small, and many did not includes rigorous 
methodology for detecting rare (but serious) complications.  
E. Rationale of the study 
Previous studies with acetaminophen have shown consistent and clinically 
important opioid-sparing effects; however these studies were unable to demonstrate 
significant reductions in opioid-related adverse events, largely because sample sizes 
were inadequate and because complications were poorly monitored. Most notably, no 
previous studies of perioperative acetaminophen used continuous pulse oximetry which 
is probably the only reliable way to detect potentially serious respiratory compromise.  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
7 
One barrier to using intravenous acetaminophen in the perioperative period is that 
it is relatively expensive compared to other NSAIDs. However, the complications including 
respiratory depression associated with increased opioid usage are extremely costly. The 
costs of using intravenous acetaminophen for preventing opioid related side effects and 
the costs of treating the associated complications has not been addressed. Furthermore, 
available studies and calculations regarding cost are not based on actual decreases in 
opioid-related side effects, but instead on unverified assumptions, making the results 
unconvincing. Therefore, assessing the cost-effectiveness of intravenous acetaminophen 
needs to be investigated as well. 
We thus propose to evaluate the opioid-sparing effect of intravenous 
acetaminophen and, more importantly, the reduction in opioid-related complications. 
Specifically, we propose to test the primary hypothesis that total duration of hypoxia 
(defined as time with SpO2 < 90%) is less in patients given intravenous acetaminophen 
than placebo. Our secondary hypotheses are that intravenous acetaminophen: 
1) decreases postoperative opioid consumption; 2) decreases postoperative pain; 
3) decreases nausea and vomiting; 4) decreases sedation; 5) improve activity; and 6) 
reduces fatigue. 
The impact of postoperative opioid related complications is not only important from 
a clinical perspective, but also from an economic standpoint. The additional cost 
attributable to opioid side effects has not been well defined and usually depends on 
estimates rather than solid data. Our study will provide data to support a full cost-benefit 
analysis, so the financial benefits of acetaminophen can be concretely evaluated. 
Opioids and analgesics have been separately shown to reduce MAC values in 
previous studies (37, 38). Acetaminophen and NSAIDs have been implicated in 
decreased anesthetic requirements, but there is no concrete evidence to support this 
theory (39, 40, 41). Measurement of BIS values during surgery will help shed some light 
on the MAC-sparing effect of acetaminophen if it exists. 
 
 
 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
8 
2. Study Objectives 
Using a randomized design and blinded assessments, our goal is to determine the 
effect of intravenous acetaminophen (versus placebo) infusion on a variety of important 
opioid-related complications and outcomes in postoperative patients. The proposed 
research will have the following aims, all of which will be assessed over 48 hours or the 
duration of hospitalization if shorter: 
Primary Aim. To assess whether intravenous acetaminophen decreases postoperative 
opioid-related respiratory depression. 
Hypothesis. Our primary hypothesis is that total duration of hypoxia (defined as time with 
SpO2 < 90%) is less in patients given intravenous acetaminophen than placebo.  
Secondary Aims.  
Secondary Aim 1. To evaluate the role of intravenous acetaminophen on postoperative 
opioid consumption.  
Hypothesis. Total opioid consumption is reduced by intravenous acetaminophen infusion.  
Secondary Aim 2. To evaluate the role of intravenous acetaminophen on postoperative 
pain.  
Hypothesis. Intravenous acetaminophen decreases time-weighted postoperative pain 
scores.  
Secondary Aim 3. To evaluate whether intravenous acetaminophen decreases nausea 
and vomiting.  
Hypothesis. The incidence of postoperative nausea and vomiting is reduced in patients 
given intravenous acetaminophen.  
Secondary Aim 4. To evaluate whether intravenous acetaminophen decreases sedation.  
Hypothesis. The incidence of postoperative sedation is reduced in patients given 
intravenous acetaminophen.  
Secondary Aim 5. To assess the effect of intravenous acetaminophen on activity after 
surgery.  
Hypothesis. Intravenous acetaminophen increases the time spend sitting and upright 
rather than lying down. 
Secondary Aim 6. To assess the effect of intravenous acetaminophen on fatigue after 
surgery.  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
9 
Hypothesis. Postoperative fatigue scores are reduced in patients given intravenous 
acetaminophen.  
Secondary Aim 7. To assess the cost-effectiveness of intravenous acetaminophen after 
surgery.  
Hypothesis. Intravenous acetaminophen reduces total cost of care from the societal 
perspective by decreasing opioid-related complications and hospital length-of-stay. 
Secondary Aim 8. To evaluate the role of intravenous acetaminophen on postoperative 
opioid-related respiratory parameters. 
Hypothesis. Intravenous acetaminophen reduces respiratory depression (defined by 
decrease in tidal volume, minute ventilation and respiratory rate) compared to placebo.  
Secondary Aim 9. To evaluate the MAC-sparing effect of acetaminophen 
intraoperatively. 
Hypothesis. Intravenous acetaminophen reduces MAC requirements when given 
intraoperatively. 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
10 
3. Method and Study Design 
A. Study Overview 
We propose to assess opioid-related side effects in patients recovering from 
elective non-cardiac surgery who will be randomly assigned to intravenous 
acetaminophen or placebo for 48 hours postoperatively. The design will be a randomized, 
double-blind, placebo-controlled trial of intravenous acetaminophen in adults having 
elective major abdominal surgery. The study will be performed at the Cleveland Clinic 
hospitals. 
B. Setting and Population 
Inclusion criteria:  
(1) Written informed consent; 
(2) 18-85 years old; 
(3) ASA Physical Status 1-3; 
(4) Scheduled for elective open or laparoscopic abdominal surgery, including 
colorectal, prostate, and hysterectomy surgeries; 
(5) Patients with anticipated hospitalization of two nights; 
(6) Expected to require parenteral opioids for at least 48 hours for postoperative 
pain; 
(7) Able to use IV PCA systems. 
Exclusion criteria:  
(1) Hepatic disease, e.g. twice the normal levels of liver enzymes; 
(2) Kidney disease, e.g. twice the normal level of serum creatinine;  
(3) Epidural analgesia or regional blocks (including TAP block); 
(4) Acetaminophen sensitivity or known allergy; 
(5) Female patients who are pregnant or breastfeeding; 
(6) Patients taking warfarin.  
C. Withdrawal Criteria  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
11 
 Patients will be free to withdraw from study at any time. Patients will also be removed 
from study at any time for adverse events, or deemed necessary for patient safety. 
D. Administration of Acetaminophen  
The investigational drug for this study is Acetaminophen 1 g per dose. The placebo 
control is 0.9% sodium chloride prepared in equal volume and infused at same rate and 
duration of acetaminophen. The Pharmacy team will have the appropriate randomization 
in case of a safety or emergency situation, and the study drug label will mention that it is 
“Acetaminophen or Normal saline”. 
E. Protocol 
Patients must meet all inclusion and exclusion criteria to be eligible for the study. 
After eligibility is confirmed, patients will receive complete information about the study 
both verbally and in writing. Informed consent must be obtained from the patients prior to 
randomization and study-specific procedures. Research fellow will also apply an 8 item 
STOP-BANG questionnaire. 
Anesthetic management will follow pre-established clinical and institutional 
guidelines. Patients will be pre-medicated, and induced per institutional routine according 
to attending anesthesiologist discretion. General anesthesia will include the standard 
monitoring for the given operation, and induction will occur after the electrocardiogram 
and monitoring equipment are placed on the patient. Induction agents may include 
sodium pentothal, propofol, or etomidate, fentanyl, rocuronium, and oxygen. Anesthesia 
will be maintained with sevoflurane or isoflurane in oxygen and air; rocuronium or 
atracurium will be given per judgment of the attending anesthesiologist. Prophylactic 
antibiotics will be given per surgical routine.  
Randomization (1:1) will be web-based and initiated at induction of anesthesia; 
allocation will thus be concealed from investigators. Randomization will be stratified 
based on chronic opioid use. Chronic opioid use will be defined as opioid use for more 
than 30 consecutive days, at a daily dose of 15 mg or more of morphine or equivalent, 
within the 3 months before surgery. The treatment groups will be intravenous 
acetaminophen and normal saline placebo.  
Acetaminophen or placebo infusion will be initiated as soon as practical in the 
operating room with 1 g (or equivalent volume) and repeated every 6 hours for the earlier 
of 48 postoperative hours of hospital discharge. Intraoperative opioids and 
benzodiazepines will be left to discretion of the anesthesiologist. However, fentanyl will 
be recommended for intraoperative analgesia, and hydromorphone for postoperative 
analgesia.  
In the PACU, patients will be given intravenous PRN bolus of hydromorphone or 
fentanyl as necessary. Subsequently, patients will be given hydromorphone or fentanyl 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
12 
PCA with standard clinical settings, with the option of fentanyl or hydromorphone for 
breakthrough pain. The blinded clinicians, according to current standard clinical protocols, 
will make adjustments for the opioid analgesic dose. Patients will be titrated to comfort 
(pain score of <4) in the PACU and ward using allowed opioids.  
Clinical evaluators for the outcomes will be blinded to group allocation and 
Pharmacy personnel not involved in evaluations will prepare the study drugs. Patients will 
be continuously monitored and recorded with a wireless pulse-oximeter starting after 
extubation in the operating room. A respiratory volume monitor will be used continuously 
for the study period and information will be recorded. Clinicians including nurses will be 
blinded to monitoring and will be required to perform their standard of care management 
after surgery.  
Other anti-inflammatory drugs will not be used intraoperatively or for the initial 48 
postoperative hours. A single dose of dexamethasone (4-8 mg) will be permitted for 
PONV prophylaxis, and inhaled steroids will be permitted as necessary to treat reactive 
airway disease. Other opioid sparing medications like gabapentin, pregabalin, ketamine 
or lidocaine patch will also not be permitted through the initial 48 postoperative hours.  
Patients will be allowed to receive prophylactic anti-emetic (first choice 
ondansetron) intraoperatively based on the risk assessment for nausea and vomiting. 
Postoperative anti-emetics for symptomatic treatment will also be allowed; again 
ondansetron will be the first choice.  
F. Measurements 
Demographic and Background Information:  
Demographic data to be obtained includes height (cm), weight (kg), age (yr), 
gender, (ASA) physical status, and self-declared ethnicity. Patients will be questioned for 
social history (tobacco) and medical history (pulmonary disease, kidney disease, diabetes 
mellitus, neurological disease, chronic pain conditions, illegal drug usage, alcohol abuse, 
myocardial infarction, previous surgery or stent placement and medications usage). 
Available preoperative laboratory tests and medication list will be recorded. Individual risk 
for nausea and vomiting will be determined using the Apfel score.  
ViSi mobile (Sotera Wireless) patient monitoring system will be used to 
continuously record noninvasive blood pressure, patient activity, posture, 3-lead ECG, 
SpO2, and respiratory rate. Data will be recorded at one-minute intervals and downloaded 
daily to a laptop. 
ExSpiron Respiratory Volume Monitor (RVM) has been shown to provide accurate 
real-time, continuous, non-invasive measurements of tidal volume, minute ventilation and 
respiratory rate. This system will be used to record respiratory data and downloaded for 
analysis.  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
13 
Data obtained from electronic medical records will include: operation time, surgery 
type, intraoperative opioid consumption, postoperative opioid consumption in PACU and 
in ward, breakthrough pain medication requirements, pain scores in PACU and ward, 
requirement of oxygen in PACU and ward, nausea and vomiting, requirement of 
antiemetics, pruritus, requirement of antihistaminic medications, requirement of naloxone, 
itching, ambulation time, flatus, ileus, bowel movements (first time, all bowel sounds at all 
quadrants), constipation, length of stay and any side effects or complications. 
Preoperative and postoperative laboratory data including but not limited to liver function 
and coagulations test results will also be collected from electronic medical records. 
Patient functionality will also be recorded including, bathing, toileting, walking and moving. 
Brief Pain Inventory and the Short Form 12 health survey (SF 12) will be completed 
before surgery, and at the 90-day follow up. Brief Pain Inventory is a practical method of 
evaluating pain severity and impact on patient function. BPI includes four rating pain 
intensity, and seven covering the impact of pain. Intensity is recorded on an ordinal scale 
from zero (no pain) to ten (worst imaginable pain). Impact of the pain section these ratings 
are made on zero-to ten numeric scales running from no interference to complete 
interference. The Short Form 12 health survey is an abbreviated version of the SF-36 
health survey, a well-established instrument to assess psychological and physical 
aspects of health related quality of life.  
Patient satisfaction with their pain treatment will be questioned after 48 hours using 
0-100 scales and we will also use Myles QoR scale to formally evaluate quality of 
recovery. Myles QoR scale is a validated scoring system allows quantification of patient’s 
early postoperative health status, which is also a description of quality of recovery. 
Patient satisfaction with the comfort of wearing the ViSi and ExSpiron devices will 
be questioned on the second post-operative day after the monitoring session is stopped. 
 
 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
14 
Primary Aim 
Duration of hypoxic events (SpO2 < 90):  
Patients will have nearly continuous pulseoxymeter monitoring and recording. 
Nurses and the study personal will be blinded to data on the monitor and standard of care 
will be provided. Data from the monitor will be downloaded daily for 48 hours 
postoperatively, incidence of hypoxia and the time spend hypoxic will be determined. We 
will be using ViSi mobile (Sotera Wireless) patient monitoring system a platform for 
comprehensive vital sign monitoring. This is a comfortable body-worn sensor that allows 
the patient to ambulate or move, providing accurate and continuous monitoring of all the 
vital signs including beat-to beat noninvasive blood pressure, patient activity, and posture. 
This system will measure 3 lead ECG, SpO2 and number of respirations continuously. 
The primary outcome will be area-under-the-curve for saturation over time with the 
threshold set at 90%.  
 
Secondary Aim 1 
Total opioid consumption, in morphine equivalents, will be the major measure of 
opioid use. However, we will also record the number of times fentanyl is given for 
breakthrough pain. 
Secondary Aim 2  
Our major outcome for pain will be time-weighted pain scores from discharge from 
the PACU until 48 hours after the end of surgery. PACU pain scores will also be compared 
separately. Sedation will be determined and recorded at roughly 4-hour by ward nurses 
per clinical routine. 
Secondary Aim 3 
Our major outcome for PONV will be the cumulative incidence of nausea and 
vomiting outcome during the initial postoperative 48 hours. However, we will also consider 
the number anti-emetic rescue treatments. 
Secondary Aim 4 
 Our major outcome for sedation will be severity of sedation, as determined by the 
Richmond Agitation Sedation Scale, during the initial 48 postoperative hours. Sedation 
will be determined and recorded by ward nurses per clinical routine. 
Secondary Aim 5  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
15 
Our major measure of activity will be the time spend while sitting or upright, as 
determined by the ViSi mobile monitoring system, during the initial 48 postoperative 
hours.  
Secondary Aim 6  
 Our major measure of fatigue will be a VRS score determined on the first 
postoperative morning.  
Secondary Aim 7 
A cost-benefit analysis will be conducted to determine the optimal strategy of IV 
acetaminophen compared to placebo. The analysis will compare the costs of the 
intervention compared to the monetary value of the benefits.  The benefits will include 
opioid medication reduction, LOS reduction, nursing time reduction, hypoxia reduction, 
PONV reduction, and any health care resource utilization reduction attributable to 
reduced opioid use in the 3 months post surgery. 
Secondary Aim 8 
Continuous ExSpiron impedance data collection will occur during PACU and 
postoperative study period. Our major outcomes will be the tidal volume, minute volume 
and respiratory rate. 
Secondary Aim 9 
 
We will conduct a secondary analysis within the subset of patients who has their 
BIS values measured. We will compare the two randomized groups on total amount of 
anesthetic gas (MAC-hours) receive from induction to extubation, using multivariable 
linear regression adjusting for the time-weighted average BIS value and any imbalanced 
baseline variables within the subset. Intraoperative BIS values and amount of anesthetic 
gas will be obtained from the Cleveland Clinic Anesthesia Record Keeping System. 
 
G. Data Analysis 
Analyses will be intent to treat. The randomized groups will first be compared for 
balance on all potentially confounding baseline variables using standard descriptive 
statistics. Any imbalanced factors will be used for adjustment in all analyses comparing 
randomized groups on outcome. 
To evaluate our primary hypothesis, we will compare patients randomized to 
acetaminophen to those randomized to placebo on the total duration of hypoxia (defined 
as time spent with SpO2 < 90%). Various graphical and tabular summaries will be 
undertaken to characterize the hypoxic events in the two study populations (e.g., reporting 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
16 
incidence of any hypoxic event, summaries of timing and duration of hypoxic events 
relative to surgery, etc.). 
To formally test our primary hypothesis, we expect that the duration of hypoxia 
outcome will exhibit a skewed distribution, with many patients having durations of zero. 
Thus, standard tests and methods for normally-distributed outcomes may not be 
applicable. Further, separate analyses need to be considered depending on whether or 
not there is a presence of chance imbalance on baseline characteristics between the 
groups. If there are no such imbalanced factors, we will utilize the two-sample Wilcoxon 
rank sum test for our primary comparison. If there are imbalanced factors to be used for 
adjustment in our analysis, we will do so by developing either a multivariable Poisson 
regression model, a multivariable negative binomial (NB) regression model, or a 
multivariable zero-inflated negative binomial (ZINB) regression model depending on the 
specific distributional characteristics of duration of hypoxia in the samples (we will choose 
the model which exhibits the best goodness of fit). In any case, a significance level of 
0.05 will be used to evaluate the primary hypothesis. 
Secondary outcomes will each be compared at the 0.005 significance level, 
reflecting a Bonferroni correction for ten simultaneous comparisons in order to maintain 
overall Type I error rate at 0.05 for the set of secondary hypotheses. Opioid consumption, 
patient-mean pain scores, total time spent sitting, total time spent upright, and fatigue 
score will be analyzed using either t-tests of multivariable linear regression models 
(depending on whether or not there are any imbalanced factors). Prior to analysis, 
morphine equivalent doses will be transformed using the logarithm in order to stabilize 
the distributions and model percent differences in geometric means. For incidence of 
nausea and vomiting, we will use either chi-squared tests or multivariable logistic 
regression models.  
Tidal volume, minute ventilation and respiratory rate will each be analyzed using 
respective mixed effects regression models.  These outcomes will be expressed as 
differences from their baseline value to indicate levels of depression throughout the 
monitoring period.  A power series correlation structure will be used to adjust analysis for 
the intra-subject correlation exhibited by multiple outcomes made within a patient; this 
structure assigns a higher degree of correlation/redundancy for measurements made 
more closely together in time than for measurements made more distant in time from one 
another.  The hypothesis of difference in average level respiratory depression between 
the acetaminophen group and placebo group will be assessed by comparing regression 
coefficients associated with the group effect in these models.  Tests for interactions with 
time (i.e., time-dependent effects of acetaminophen on depression outcomes) will be 
performed, and, if significant, results will be expressed as a function of monitoring time. 
All analyses will be performed using R statistical software for 64-bit Microsoft 
Windows (The R Foundation for Statistical Computing, Vienna, Austria). 
Economic Analysis 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
17 
The impact of postoperative opioid related complications is significant from not only 
a clinical standpoint but from an economic standpoint. The additional cost attributable to 
opioid side effects has not been well defined and usually depends on estimations rather 
than solid data. Our study will provide a cost-benefit analysis where the costs and benefits 
in monetary terms of the outcomes of multiple benefits can be compared. 
A cost-benefit analysis will be conducted to determine the optimal strategy for 
economic outcomes related to IV acetaminophen and surgery. A cost benefit analysis is 
based on welfare economics and allows us to determine whether the outcome/benefit is 
worth achieving given the opportunity cost to society of all the resources consumed to 
achieve this outcome (42). In cost benefit analysis, all costs and benefits are measured 
in monetary terms. For benefits that cannot be directly measured monetarily, they are 
valued using a human capital, revealed preferences, or stated willingness to pay (WTP) 
method (43). By using uniform unit of benefit, multiple benefits can be included the 
analysis as compared to a cost-effectiveness analysis where only one unit of effect or 
benefit can be compared. In a cost-benefit analysis, the incremental difference in costs 
and benefits between interventions being evaluated determines the optimal strategy of 
choice. 
To undertake this form of analysis, a decision analytic model using Treeage Pro® 
will be developed. A decision analytic model is a systematic, quantitative approach to 
decision making and can aid in health-care resource allocation. The decision analytic 
model will compare two possible intervention arms: A- IV Acetaminophen and B-Placebo. 
All possible outcomes will be incorporated into the model. PONV reduction will be 
incorporated as a decision node.  Opiod reduction, LOS reduction, nursing time reduction, 
hypoxia reduction, and 3-month health care utilization benefits will be incorporated at the 
terminal nodes. A simplified decision tree is presented in Figure 1. A hospital/payer 
perspective will be adopted and include all relevant costs and outcomes. Only costs and 
benefits relevant to the interventions in question will be included. All outcome probabilities 
used in the model will be determined from the clinical trial.  
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
18 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
19 
Figure 1 – Skeleton Decision Tree – IV Acetaminophen vs. Placebo 
Costs to be included will be the costs of the intervention drugs, the cost of adverse 
events, cost of any additional labor required, and cost of any healthcare resources 
required in the 3 months post surgery.  These resources may include ER visits, physician 
visits or hospitalizations attributable to, and reduction of health care resource use in the 
3 months post surgery. The opioid reduction will be valued by determining quantity and 
cost using the average wholesale drug acquisition costs. These costs will be sourced from 
the Elselvier Rx Verify database.  The value of LOS will be valued based on 
Medicare/Medicaid reimbursement schedules. The value of avoiding PONV will be 
determined from a willingness to pay analysis (contingency valuation) as published at the 
time of analysis (40, 41). As with costs, all benefits will be adjusted to the same base year 
using the Medical Component of the Consumer Price Index and all future benefits will be 
discounted at a rate of 3%.  
The determined costs and benefits for each arm of the decision tree will be 
incorporated. The analysis of the model will use the costs, benefits and probabilities of 
each arm of the decision tree.  The analysis outcome will be a cost benefit ratio for each 
arm. The incremental cost-benefit ratio will be calculated for the interventions. Depending 
on the results, one intervention may be dominated in terms of cost and benefit or the 
optimal strategy may be dependent on willingness to pay for additional units of benefit.  
The initial analysis would use direct clinical trial data. One criticism of clinical trial 
data, especially when it is used in an economic evaluation is that its outcomes can’t 
always be generalized to other settings (42). Through the use of economic modeling, 
clinical trial outcomes can be modeled to real world conditions. Models can also 
extrapolate data beyond the clinical trial, link intermediate clinical endpoints to final 
outcomes, and simulate head to head comparisons of interventions where a trial does not 
exist. For this study, complex sensitivity analysis will be conducted to test the robustness 
of the results to variability and uncertainty in the models values and its effect on the choice 
of optimal strategy. The model will be populated with not just point estimates, but with the 
range of data values including distributions.  
Variability and uncertainty in the model will be analyzed from 3 aspects; variability 
in the population, uncertainty in the structure of the model, and uncertainty of the variables 
used within the model. Variability of the population will be tested using a Monte Carlo 
Microsimulation. This analysis involves running one patient at a time through the model 
with the events based on the underlying probabilities and a random number generator 
within the model. This analysis simulates differences in populations and the distribution 
of potential outcomes including optimal intervention choice can be plotted. Uncertainty 
within the model will be analyzed using one-way sensitivity analysis. This analysis 
involves varying the value of one variable at a time within the predetermined range. From 
this analysis will be conducted where one value will be varied at a time. From this analysis, 
the variables who are the biggest drivers of changes in the model will be identified and 
summarized with a tornado diagram. To test the uncertainty of the variables used in the 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
20 
model, probabilistic sensitivity analysis will be conducted. This form of analysis allows the 
uncertainty of all the variables in the model to be assessed at the same time. The values 
of variables are sampled from the distributions within the model. Using these results, the 
incremental cost benefit ratios will be determined with confidence intervals. Incremental 
net benefits will also be determined by determining a cost-effectiveness acceptability 
curve. This curve summarizes what proportion of time the optimal strategy will indeed be 
the optimal strategy as it depends on willingness to pay. 
From all the analyses presented above, a transparent, easy to follow cost-benefit 
summary will be produced to aid persons in decision making positions. The summary will 
include the costs and benefits of each intervention, the incremental costs and benefits 
between the interventions, the cost benefit ratio of the interventions, and the incremental 
cost benefit ratio between the interventions. The uncertainty around the results will also 
be summarized to show that the optimal strategy is the choice strategy in ‘what’ 
percentage of time and for ‘what’ variable values.  
H. Sample Size Considerations 
VISION is a large prospective observational cohort study with the primary aim to 
evaluate major vascular events in patients undergoing noncardiac surgery. We analyzed 
preliminary data on postoperative SpO2 from the all 833 patients who had >12 hours 
continuous monitoring with <20% missing data (Table 1).  Each patient’s SpO2-versus-
time data was first smoothed using kernel regression in order to remove excess variability 
(see Figure 2 for examples). 
Total duration of hypoxia was then computed for each patient according to their 
smoothed SpO2-versus-time profiles.  The distribution of total duration of hypoxia is 
summarized in Table 1 below, under “Preliminary Observational Data”: 
 
 
Table 1 
  
Preliminary  
Observational 
Data 
N (Percent) 
Assumed 
Percentage 
Under  
Acetaminophen 
No Hypoxia 
461 (55.3%) 
 
65% 
 
Hypoxia <1 Hour 
33 ( 4.0%) 
10% 
Hypoxia 1-2 Hours 
59 ( 7.1%) 
6% 
Hypoxia 2-4 Hours 
67 ( 8.0%) 
5% 
Hypoxia 4-12 Hours 
118 (14.2%) 
 
  7% 
Hypoxia >12 Hours 
95 (11.4%) 
7% 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
21 
 
 
Figure 2:  Time series of SpO2 (green lines) for a stratified random sample of patients (i.e., two 
from each hypoxia classes:  no hypoxia, hypoxia <1h, hypoxia 1-2h, hypoxia 2-4h, hypoxia 4-12h, 
and hypoxia >12h). Curves representing kernel smooth estimates of each time series – by which 
the duration of hypoxia outcomes are defined – are overlayed (black lines). 
 
For sample size planning purposes, it suffices to use power calculations for the 
two-sample Wilcoxon rank sum test (i.e., the planned test in the absence of imbalanced 
potential confounding factors). Assuming that acetaminophen reduces hypoxia risk such 
that the distribution of total duration of hypoxia is that given in the right column of Table 
1, a minimum of 528 patients would be required for the Wilcoxon test to have 90% power 
to identify a significant difference at the 0.05 level.  Thus, without adjusting for interim 
analyses, we would enroll 528 patients in our study. 
Interim Monitoring 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
22 
Three interim analyses and one final analysis will be conducted.  This allows for 
the possibility of stopping the trial early for efficacy or for futility (should the results indicate 
either outcome), at the potential expense of increasing the maximum possible study 
sample size (i.e., that which would be used if the trial is not stopped early). 
Stopping boundaries are formally defined according to respective Type I (false 
positive) and Type II (false negative) error spending rates.  As mentioned above, the total 
Type I error rate for the primary hypothesis will be controlled over the entire study period 
at 5%.  The Type II error rate for the entire study will be controlled at 10%, corresponding 
to 90% power.  We used gamma error spending functions with rate parameters of -4 for 
Type I error and -2 for Type II error (Figure 3). 
Interim analyses will be conducted at equally spaced intervals: 25%, 50%, 75%, 
and 100% of maximum planned sample size, respectively.  The critical p-values of our 
Wilcoxon rank sum test at each of these four analyses (defined by the curves in Figure 
3) will be P<0.0016, P<0.0048, P<0.0147, and P<0.0440 for efficacy and P>0.9572, 
P>0.7186, P>0.2389, and P>0.0441 for futility (Figure 4).   The cumulative probability of 
crossing a boundary at the 1st through 4th interim analyses, assuming that hypothesized 
treatment effect reflects the true population difference, will be 0.04, 0.31, 0.80 and 1.0, 
respectively.  
 
 
Figure 3 – Type I (alpha) and Type II (beta) error spending functions over the accrued information 
fraction – i.e., the proportion of the maximum total sample size accrued. 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
23 
 
Adjusting for interim analyses, the maximum possible sample size will be N=580 
patients, corresponding to interim analyses at N=145, N=290, N=435 and 580, 
respectively, as needed.    
Though boundaries may be crossed, imbalanced covariables may yet remain (and 
thus the need to use the multivariable Poisson/negative binomial regression model to 
account for chance imbalances). Stopping criteria under these count regression models 
are difficult to define, as two effects result from such analyses (the odds ratio for zero 
versus positive hypoxia outcome as well as the ratio of means among patients with 
positive outcomes).  We will report balance on covariables and results from the count 
regression models at each stage of the study to the Data Safety Monitoring Board. Figure 
3). 
 
 
 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
24 
Figure 4 – Type I (alpha) and Type II (beta) error boundaries over the accrued sample size. 
 
 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
25 
I. References 
1) Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute 
postoperative pain. Curr Opin Anaesthesiol2009 Oct;22(5):588-93. 
2) Brennan TJ, Kehlet H. Preventive analgesia to reduce wound hyperalgesia and 
persistent postsurgical pain: not an easy path. Anesthesiology2005 
Oct;103(4):681-3. 
3) Desborough JP. The stress response to trauma andsurgery. Br J 
Anaesth 2000;85:109–17. 
4) W i l m o r e  
D W .  
F r o m  
C u t h b e r t s o n  
t o  
f a s t -
t r a c k  surgery: 70 years of progress in reducing stress insurgical 
patients. Ann Surg 2002;236:643–8. 
5) Holte K, Kehlet H. Postoperative ileus: A preventableevent. Br J 
Surg 2000;87:1480–93. 
6) Nikolajsen L, Minella CE. Acute postoperative pain asa risk factor for chronic 
pain after surgery. Eur J PainSuppl 2009;3:29–32. 
7) Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of 
predictive factors. Anesthesiology 2000;93:1123–33. 
8) Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: 
results from a national survey suggest postoperative pain continues to be 
undermanaged. Anesth Analg. 2003 Aug;97(2):534-40, 
9) Phillip DM. JCAHO Pain management standards are unveiled. JAMA 2000; 
284: 428–29. 
10) Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: 
pharmacological and clinical aspects of ketamine and gabapentinoids. 
Pharmacol Res. 2012 Apr;65(4):411-29.  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
26 
11) White PF, Kehlet H, Neal JM, Schricker T, Carr DB, Carli F; Fast-Track Surgery 
Study Group. The role of the anesthesiologist in fast-track surgery: from 
multimodal analgesia to perioperative medical care. Anesth Analg. 2007 
Jun;104(6):1380-96. 
12) Beck A, Salem K, Krischak G, Kinzl L, Bischoff M, Schmelz A. Nonsteroidal 
anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology 
and orthopedics effects on bone healing. Oper Orthop Traumatol. 2005 
Dec;17(6):569-78. 
13) Smith HS. Perioperative intravenous acetaminophen and NSAIDs. Pain Med. 
2011 Jun;12(6):961-81. 
14) Argoff C. Mechanisms of pain transmission and pharmacologic management. 
Curr Med Res Opin. 2011 Oct;27(10):2019-31. 
15) Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari 
D. Adverse effects associated with non-opioid and opioid treatment in patients 
with chronic pain. Clin Drug Investig. 2012 Feb;32 Suppl 1:53-63.  
16) Barletta JF. Clinical and economic burden of opioid use for postsurgical pain: 
focus on ventilatory impairment and ileus. Pharmacotherapy. 2012 Sep;32(9 
Suppl):12S-8S.  
17) Chieh Yang Koo and Matthias Eikermann. Respiratory Effects of Opioids in 
Perioperative Medicine. The Open Anesthesiology Journal, 2011, 5, (Suppl 1-
M6) 23-34. 
18) Dahan A, Aarts L, Smith TW. Incidence, Reversal, and Prevention of Opioid-
induced Respiratory Depression. Anesthesiology. 2010 Jan;112(1):226-38.  
19) Joint Commission, Sentinel Event Alert, Issue 49, August 8, 2012. 
20) Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. 
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
27 
patient-episodes. 
PLoS 
One. 
2009;4(2):e4439. 
doi: 
10.1371/journal.pone.0004439. 
21) Willens JS, Junquist CR, Cohen A, Polomano R. ASPMN survey--nurses' 
practice patterns related to monitoring and preventing respiratory depression. 
Pain Manag Nurs. 2013 Mar;14(1):60-5.  
22) http://www.apsf.org/newsletters/pdf/winter2007.pdf 
23) Gupta YK, Bhandari P, Chugh A, Seth SD, Dixit KS, Bhargava KP. Role of 
endogenous opioids and histamine in morphine induced emesis. Indian J Exp 
Biol. 1989 Jan;27(1):52-4. 
24) S J Panchal, P Müller-Schwefe, and J I Wurzelmann. Opioid-induced bowel 
dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007 
July; 61(7): 1181–1187.  
25) Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore 
AJ. Postoperative ileus: it costs more than you expect. J Am Coll Surg. 2010 
Feb;210(2):228-31. 
26) Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of 
paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur 
J Pharmacol 2006;531:280–1. 
27) Björkman R. Central antinociceptive effects of nonsteroidal anti-inflammatory 
drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol 
Scand Suppl 1995;103:1–44. 
28) Hogestatt ED, Jönsson BA, Ermund A, et al. Conversion of acetaminophen to 
the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-
dependent arachidonic acid conjugation in the nervous system. J Biol Chem 
2005; 280:31405–12. 
29) Björkman R, Hallman KM, Hedner J, Hedner T, Henning M. Acetaminophen 
blocks spinal hyperalgesia induced by NMDA and substance P. Pain 1994; 
57:259–64. 
30) Jones VM. Acetaminophen injection: a review of clinical information. J Pain 
Palliat Care Pharmacother. 2011; 25(4):340-9.  
31) Duggan ST, Scott LJ. Intravenous paracetamol (acetaminophen). Drugs. 
2009; 69(1):101-13.  


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
28 
32) Pasero C, Stannard D. The role of intravenous acetaminophen in acute pain 
management: a case-illustrated review. Pain Manag Nurs. 2012 Jun;13(2):107-
24.  
33) Lachiewicz PF. The role of intravenous acetaminophen in multimodal pain 
protocols for perioperative orthopedic patients. Orthopedics. 2013 Feb 
1;36(2):15-9.  
34) Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-
effects and consumption after major surgery: meta-analysis of randomized 
controlled trials. Br J Anaesth. 2005 Apr;94(4):505-13. 
35) Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with 
acetaminophen, 
nonsteroidal 
antiinflammatory 
drugs, 
or 
selective 
cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer 
advantages over morphine alone? Meta-analyses of randomized trials. 
Anesthesiology. 2005 Dec;103(6):1296-304. 
36) Apfel CC, Turan A, Souza K, Pergolizzi J, Hornuss C. Intravenous 
acetaminophen reduces postoperative nausea and vomiting: A systematic 
review and meta-analysis. Pain. 2013 May;154(5):677-89.  
37) Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: 
pharmacological and clinical aspects of ketamine and gabapentinoids. 
Pharmacol Res. 2012 Apr;65(4):411-29.. 
38) Glass PS, Gan TJ, Howell S, Ginsberg B. Drug interactions: volatile anesthetics 
and opioids. J Clin Anesth. 1997 Sep;9(6 Suppl):18S-22S. 
39) Jeff C. H. Ko, DVM, MS, DACVA Douglas N. Lange, DVM, DACVS Ronald E. 
Mandsager, DVM, DACVA Mark E. Payton, PhD Christine Bowen, BS Atsushi 
Kamata, DVM Wei-Chen Kuo, DVM, MS. Effects of butorphanol and carprofen 
on the minimal alveolar concentration of isoflurane in dogs. JAVMA, October 
1, 2000, Vol. 217, No. 7, Pages 1025-1028. 
40) Butch KuKanich, Tara Bidgood, Oliver Knesl. Clinical pharmacology of 
nonsteroidal anti-inflammatory drugs in dogs. Veterinary Anaesthesia and 
Analgesia, Volume 39, Issue 1, pages 69–90, January 2012. 
41) Benito J, Aguado D, Abreu MB, García-Fernández J, Gómez de Segura IA. 
Remifentanil and cyclooxygenase inhibitors interactions in the minimum 
alveolar concentration of sevoflurane in the rat. Br J Anaesth. 2010 
Dec;105(6):810-7. doi: 10.1093/bja/aeq241. Epub 2010 Sep 22. 


Effect of Acetaminophen on Postoperative Opioid-related Complications  Turan, et 
al. 
 
 
 
 
 
 
 
 
 
29 
42) Drummond, M., Sculpher, M., Torrance, G., O’Brien, B., Stoddart, G.: Methods 
for the Economic Evaluation of Health Care Programmes. 3rd ed. 2005, Oxford: 
Oxford University Press. 
43) Gray, A., Clarke, P., Wolstenholme, J., Wordsworth, S.: Applied Methods of 
Cost-effectiveness Analysis in Health Care. 2011, Oxford, Oxford University 
Press. 
44) Weinsten, MC., Siegel, JE, Gold, MR., Kamlet, MS., Russell, L.B: 
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. 
JAMA 1996; 276:1253-1258 
45) Gan, T., Sloan, F., de L Dear, G., El-Moalem, H., Lubarsky, A: How Much are 
Patients Willing to Pay to Avoid Postoperative Nausea and Vomiting?. 
Anesthesia and Analgesia 2001; 92:393-400 
46) Van den Bosch, J., Bonsel, G., Moons, K., Kalkman, C: Effect of Postoperative 
Experiences on Willingness to Pay to Avoid Postoperative Pain, Nausea and 
Vomiting. Anesthesiology 2006; 104(5):1033-9 
47) Buxton, MJ (Buxton, MJ); Drummond, MF (Drummond, MF); VanHout, BA 
(VanHout, BA); Prince, RL (Prince, RL); Sheldon, TA (Sheldon, TA); Szucs, T 
(Szucs, T); Vray, M (Vray, M). HEALTH ECONOMICS Volume: 6 Issue: 3 
Pages: 
217-227 
DOI: 
10.1002/(SICI)1099-1050(199705)6:3<217::AID-
HEC267>3.3.CO;2-N Published: MAY-JUN 1997